top of page
Browse by category
Search


Study provides the first visual evidence of lipid breakdown at the single-droplet level in living cells
A research team has developed a fluorescent probe that allows scientists to visualise how individual lipid droplets break down inside living cells in real-time. The probe changes its fluorescence properties depending on the chemical composition of each droplet, which allows researchers to observe not only their location within cells, but also their metabolic activity during lipid breakdown. The findings may contribute to the development of new strategies to treat metabolic di


Severity of obesity closely associated with likelihood of disease burden
Obesity severity is incrementally associated with a broad range of cardiometabolic and renal disease burden, as discovered by researchers at Pennington Biomedical Research Center. In a presentation by Dr Florina Corpodean titled, ‘Associations of Obesity Severity with Cardiometabolic and Renal Disease Burden in the United States," at ObesityWeek 2025, she explored the relationship through a cross-sectional study of data from the US Behavioral Risk Factor Surveillance System s


Mazdutide 9 mg achieves up to 20.1% weight loss as GLORY-2 Study meets primary and all key secondary endpoints
Outcomes from the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) has met the primary endpoints and all key secondary endpoints. Innovent Biologics plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in the near term. GLORY-2 is


Survey: Most Americans view obesity as a chronic disease deserving insurance coverage
Nearly two-thirds of Americans (63%) know that obesity is a chronic disease rather than a personal failure and more than 8 in 10 believe that insurance should cover its treatment, whether it be medications or surgeries, according to a new nationwide survey conducted by The Harris Poll on behalf of the American Gastroenterological Association (AGA). Adult Obesity Rate by State, 2024 (State of Obesity 2025: Better Policies for a Healthier America’, Trust for America’s Health) "


Journal watch 19/11/2025
Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including long-term outcomes of RYGB vs SG, gallstone formation post RYGB and SG, combination of OAGB with modified fundoplication improves GERD-HRQL score, Brazilian experts publish guideline on the management of obesity and prevention of CVD and obesity-associated complications, and mor


Tirzepatide may only temporarily suppress ‘food noise’
A brain-computer interface reveals the tirzepatide has a short-term or incomplete effect on related brain activity in a patient with obesity, calling for further study, a study by University of Pennsylvania School of Medicine has found. The nucleus accumbens on a brain CT of a patient (Credit: Penn Medicine) The research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, may be able to treat
Browse by tag






bottom of page
